Marie Bleakley
Overview
Explore the profile of Marie Bleakley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Gore S, Blyth E, Bleakley M, Lee K, Micklethwaite K, Gowrishankar K
Blood Adv
. 2025 Jan;
PMID: 39813621
T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed towards acute myeloid leukaemia (AML), a particularly challenging disease. Chimeric antigen receptor...
3.
Naru J, Othus M, Lin C, Biernacki M, Bleakley M, Chauncey T, et al.
EJHaem
. 2024 Dec;
5(6):1243-1251.
PMID: 39691254
Introduction: Acute myeloid leukemia (AML) remains one of the deadliest hematopoietic malignancies. A better understanding of the molecular biology governing AML may lead to improved risk stratification and facilitate the...
4.
Biernacki M, Bleakley M
Expert Rev Hematol
. 2024 Dec;
18(1):21-31.
PMID: 39667756
Introduction: T cells engineered to express antigen-specific T cell receptors (TCR; TCR-T) are a promising class of immunotherapeutic for patients with hematologic malignancies. Like chimeric antigen receptor-engineered T cells (CAR-T),...
5.
Cox E, Summers C, Milano F, Dahlberg A, Bleakley M, Sandmaier B, et al.
Ann Hematol
. 2024 Jul;
103(9):3737-3743.
PMID: 39003390
With advancements in novel therapeutics, it is unclear whether third hematopoietic cell transplantation (HCT3) has a place in the treatment of recurrent hematopoietic malignancies. We evaluated patients with hematologic malignancies...
6.
Pullarkat S, Black G, Bleakley M, Buenrostro D, Chapuis A, Hirayama A, et al.
PLoS One
. 2024 Jun;
19(6):e0303057.
PMID: 38843256
As adoptive cellular therapies become more commonplace in cancer care, there is a growing need to monitor site-specific localization of engineered cells-such as chimeric antigen receptor T (CAR-T) cells and...
7.
Krakow E, Brault M, Summers C, Cunningham T, Biernacki M, Black R, et al.
Blood
. 2024 Apr;
144(10):1069-1082.
PMID: 38683966
Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific...
8.
Weber E, Bleakley M, Cronk J, Shah N, Perna F
Mol Ther
. 2024 Feb;
32(3):563-564.
PMID: 38340733
No abstract available.
9.
10.
Biernacki M, Lok J, Black R, Foster K, Cummings C, Woodward K, et al.
J Immunother Cancer
. 2024 Jan;
11(12).
PMID: 38164756
Background: Myelodysplastic syndromes (MDS) arise from somatic mutations acquired in hematopoietic stem and progenitor cells, causing cytopenias and predisposing to transformation into secondary acute myeloid leukemia (sAML). Recurrent mutations in...